Clinical Outcomes Are Evidence-Based.
Your Marketing Should Be Too.
Revenue marketing for healthcare and life sciences is the discipline of connecting every marketing investment directly to measurable pipeline and closed contracts, within the regulatory and clinical evidence constraints of the industry. Healthcare companies sell complex solutions through buying cycles that run 18 to 24 months and involve purchasing committees that span clinical, administrative, IT, legal, and procurement stakeholders, each with different decision criteria, different information needs, and different approval authority. Revenue marketing builds systems that serve all of those buyers simultaneously, generate demand that passes clinical scrutiny, and measure what marketing contributed to contracts signed rather than leads generated.
Most healthcare marketing functions operate as clinical communications and event teams. They produce white papers, manage medical congress presence, coordinate KOL programs, and send newsletters to HCP databases. None of that is wrong. None of it is a demand generation system with measurable pipeline contribution. The healthcare and life sciences companies growing fastest are treating marketing as a revenue function: identifying buyers before they issue an RFP, nurturing multi-stakeholder committees through long evaluations, and giving the CFO a dashboard that proves what marketing contributed to contracts closed.
TPG's RM6 framework gives healthcare companies a maturity model and execution roadmap calibrated to clinical evidence requirements, 24-month buying cycles, IDN and health system purchasing committees, and the FDA and HIPAA regulatory constraints that govern every marketing communication. We start every healthcare engagement with an RM6 diagnostic to score current marketing maturity across six pillars and identify the three to five highest-impact moves for the next 90 days, all within your regulatory framework.
Evidence-based marketing is not just a positioning statement. It is a content architecture, a claim library, a review workflow, and a measurement system. When those four things are built correctly, healthcare marketing generates revenue at the same standard of rigor your clinical teams apply to everything else.
Healthcare & life sciences segments TPG serves
Revenue Marketing Strategy for Healthcare Companies
How to build a marketing strategy that generates pipeline within FDA and HIPAA constraints, without treating compliance as a reason not to market aggressively.
How do healthcare companies build a revenue marketing strategy that satisfies both the CMO's clinical standards and the CFO's growth targets?
Healthcare companies build a revenue marketing strategy that satisfies both clinical and commercial stakeholders by separating the regulatory conversation from the strategy conversation. The regulatory conversation answers: what can we say, to whom, with what claims, through what channels, with what disclosures. That conversation belongs to medical-legal-regulatory review. The strategy conversation answers: which buyer segments generate the most pipeline, what does the decision journey look like for our highest-value accounts, and where is marketing currently absent from that journey. Conflating these two conversations is the most common reason healthcare marketing strategies fail. Compliance says no to too many things, marketing runs generic programs that do not move pipeline, and neither function generates the evidence-based revenue contribution the CFO expects.
TPG's RM6 diagnostic scores your healthcare marketing maturity across 49 capabilities and produces a prioritized roadmap that sequences the work by revenue impact: which segment to pursue first, which stakeholder in the buying committee is underserved by current marketing, and which programs should be stopped because they generate activity but not pipeline.
Evidence-Based Demand Generation for Healthcare
How to generate qualified pipeline from clinical and administrative buyers who require evidence, not campaigns, before they will engage.
How do healthcare companies generate demand from clinical and administrative buyers who dismiss marketing claims without evidence?
Healthcare and life sciences demand generation fails when it applies consumer or generic B2B marketing frameworks to buyers who operate inside evidence hierarchies. A Chief Medical Officer does not respond to product campaigns the way a software buyer does. They respond to peer-reviewed outcomes data, KOL validation, and health system reference networks. A hospital administrator does not respond to feature messaging. They respond to total cost of ownership analysis, regulatory compliance documentation, and references from comparable health systems that have implemented the solution and achieved measurable results. Demand generation for healthcare works when the content and programs are built to the evidence standard each buyer type requires, and distributed through the channels where those buyers actually research vendors: clinical publications, medical society platforms, LinkedIn, and increasingly, AI answer engines.
TPG builds evidence-based demand generation programs for healthcare companies that include pre-approved clinical claim libraries, MLR-workflow-integrated content production for regulated segments, peer reference programs, and digital nurture sequences calibrated to 24-month evaluation cycles. Healthcare clients running TPG-designed demand generation programs average 188 percent pipeline growth within 18 months.
ABM for Healthcare Companies Selling to Hospitals & Health Systems
How to orchestrate coordinated marketing and sales activity across the six-stakeholder buying committee at your highest-value IDN and health system targets.
How does ABM work for healthcare companies selling to integrated delivery networks, hospitals, or health systems?
ABM for healthcare companies selling to hospitals and IDNs requires mapping a buying committee that is among the most complex in B2B sales. A health system purchase decision typically involves six or more stakeholders: the clinical lead who validates clinical evidence, the IT team who evaluates integration and security, the CFO who approves the budget, legal and compliance who review vendor contracts and HIPAA coverage, the value analysis committee who conducts formal vendor qualification, and operations leadership who assess workflow integration impact. Most healthcare marketing programs reach one or two of these stakeholders. ABM reaches all of them, simultaneously, with content that matches each stakeholder's specific evidence standard and decision timeline.
TPG has implemented ABM programs for 28+ healthcare and life sciences clients. Our healthcare ABM implementations are built with HIPAA compliance architecture from the first program design, use intent data to identify health systems actively evaluating in your category, and deliver multi-stakeholder content sequences across LinkedIn, direct outreach, and field marketing that are coordinated with sales so the account sees consistent messaging across every channel. Healthcare ABM programs average 40 to 60 percent higher conversion from target IDN and health system accounts compared to broad demand generation.
HIPAA-Compliant MarTech for Healthcare Companies
How to select and implement marketing technology that passes HIPAA security review, signs a BAA, and integrates with clinical and administrative systems.
What marketing technology platforms work for healthcare companies and which ones are HIPAA compliant?
The right MarTech platform for a healthcare company depends on your specific regulatory obligations, the clinical or administrative systems you need to integrate with, and the scale and complexity of your marketing programs. The non-negotiable requirement for any healthcare marketing technology that touches data about patients, providers, or health information is Business Associate Agreement coverage. Any vendor who handles PHI on your behalf must sign a BAA. Marketing automation platforms that sign BAAs for covered healthcare customers include Salesforce (via Health Cloud and Marketing Cloud), HubSpot (for covered entities), Marketo (Adobe), and Oracle Eloqua. Veeva CRM and Veeva Vault are standard in pharmaceutical and medical device commercial operations for their FDA-compliant content management and HCP engagement audit capabilities. Microsoft Dynamics is used at healthcare organizations already operating the Microsoft stack with Azure-hosted, HIPAA-eligible infrastructure.
TPG is platform-agnostic and certified across all major healthcare MarTech platforms. We run HIPAA-aware platform selection processes evaluating BAA coverage, PHI data handling, clinical system integration requirements, and regulatory content management needs before recommending any platform. We never select a platform based on partner relationships.
Every MarTech implementation TPG builds for healthcare clients includes BAA execution with all covered vendors, PHI data classification and segregation architecture, consent management infrastructure for all marketing communications, and audit trail configuration for HIPAA Security Rule compliance. These are architecture decisions, not afterthoughts.
For pharmaceutical and medical device clients, every MarTech implementation includes pre-approved promotional claim libraries, medical-legal-regulatory (MLR) review workflows built into campaign production systems, 21 CFR Part 11-compliant audit trails for electronic records, and controls on comparative effectiveness claims and off-label content. TPG has implemented FDA-compliant marketing systems for pharma, biotech, and medtech companies across multiple therapeutic areas and device categories.
AI Marketing for Healthcare & Life Sciences Companies
How healthcare companies use AI to identify buying signals earlier, personalize at scale, and accelerate pipeline without creating HIPAA or FDA exposure.
How do healthcare and life sciences companies use AI in marketing without violating HIPAA or FDA regulations?
Healthcare companies use AI in marketing safely by restricting AI model inputs to non-PHI data and ensuring any AI system touching data that could constitute protected health information operates under a BAA and within HIPAA Security Rule requirements. Safe AI marketing applications in healthcare include third-party intent data analysis that identifies health systems or physician practices researching solutions in your category without accessing any clinical or patient data, predictive lead scoring built on CRM engagement and firmographic signals rather than clinical records, content personalization using persona and segment-level attributes rather than individual provider or patient data, and marketing attribution modeling that connects program activity to pipeline without accessing clinical records or prescribing data. AI applications that require careful HIPAA and FDA review before deployment include systems that infer prescribing patterns, access health system clinical metrics that could constitute PHI, or generate content making clinical claims about therapeutic products.
TPG's R.A.I.N. framework is built with healthcare compliance in mind. Every AI marketing system we implement includes data classification to ensure PHI segregation, BAA coverage for all AI components touching potentially protected data, and human-in-the-loop review protocols for any AI-generated content subject to FDA promotional regulations.
Marketing Operations & RevOps for Healthcare Companies
How to build the HIPAA-compliant data and process infrastructure that makes revenue marketing scale across long cycles and multi-stakeholder accounts.
What does RevOps infrastructure need to look like for a healthcare company with HIPAA obligations and 24-month sales cycles?
RevOps infrastructure for healthcare companies needs four components that generic B2B RevOps implementations do not include. A HIPAA-compliant data architecture that classifies all data by PHI risk, routes data through BAA-covered systems, and maintains audit trails on all marketing communications that touch provider or patient data. A consent management framework that captures and stores opt-in records for all HCP and administrator communications in a form that satisfies HIPAA, GDPR, and applicable state privacy laws. A 24-month-capable attribution model that holds influence data across buying cycles that span multiple fiscal quarters and connects to contract value at close rather than MQL count. And a multi-stakeholder account tracking model that records engagement across all buying committee members at the same health system or IDN without mixing individual contact records in ways that create PHI risk.
TPG builds RevOps systems for healthcare companies that include all four layers, covering platform configuration, data architecture design, HIPAA compliance review integration, and the organizational process changes that make the data accurate enough for the CFO to use in budget allocation decisions.
Pipeline Acceleration for 24-Month Healthcare Sales Cycles
How to compress healthcare and life sciences evaluation cycles without undermining the clinical evidence process that governs purchase decisions.
How do healthcare companies accelerate 24-month sales cycles without cutting corners on the clinical evidence process buyers require?
Healthcare sales cycles are long for two reasons: legitimate clinical due diligence that must not be rushed, and unnecessary friction that accumulates because marketing is not proactively removing barriers. The legitimate clinical due diligence, evidence review, integration testing, value analysis committee evaluation, requires the time it requires. Marketing cannot and should not compress that. What marketing can do is remove every other source of delay: the six weeks it takes for a prospect to get a ROI model because sales has to build it manually, the three months a health system spends in reference checking because no one has automated the reference process, the two months of contract drafting because the legal team is seeing the vendor's BAA for the first time. All of those delays are marketing solvable. None of them are clinical necessity.
TPG builds pipeline acceleration programs for healthcare companies that deploy ROI and total cost of ownership tools at the right evaluation stage, structured peer reference programs matched by health system size, patient volume, and clinical application, and pre-executed BAA templates with legal pre-approval, all designed to eliminate the non-clinical delays that extend already long cycles. Healthcare clients using these programs see 25 to 40 percent shorter average time from qualified opportunity to contract signed.
Content Strategy for Clinical & Administrative Healthcare Buyers
How to produce content that meets the evidence standards of clinical buyers and the business standards of administrative buyers, within FDA and HIPAA constraints.
What content formats work for healthcare buyers who require clinical evidence, not marketing claims?
Healthcare content strategy works when it is built around the evidence hierarchy each buyer type uses to make decisions, not around the brand narrative the marketing team wants to tell. Clinicians evaluate by peer-reviewed publications, randomized controlled trial data, independent outcomes studies, and references from peer institutions that have achieved measurable clinical results. They are trained to identify promotional bias and discount any content that does not meet their evidence standard. Hospital administrators evaluate by total cost of ownership analysis, implementation case studies from comparable health systems, regulatory and compliance documentation, and vendor financial stability evidence. Health IT buyers evaluate by security certifications, EHR and EMR integration documentation, uptime and SLA specifics, and implementation timeline evidence. Formulary and pharmacy committees require FDA-approved labeling, comparative effectiveness data, and pharmacoeconomic analysis built to the standards their committee uses.
TPG builds healthcare content strategies that map specific content formats to specific buying committee personas and evaluation stages, with a regulatory-review workflow built into production so content reaches market faster and with lower compliance risk. For all healthcare buyer types, content distribution now requires AEO optimization because clinical and administrative buyers increasingly use AI assistants to research vendors before engaging sales.
AXO: AI Visibility for Healthcare & Life Sciences Brands
How to ensure your healthcare company is recommended when hospital administrators, clinical leaders, and health IT buyers ask AI for vendor recommendations.
How do healthcare and life sciences companies get recommended by AI systems when buyers research vendors?
Healthcare and life sciences companies get recommended by AI systems by structuring their content around the specific questions clinical and administrative buyers ask AI assistants at the beginning of vendor research. This research phase is happening earlier than most healthcare companies realize and before most of them have created the content that would make them appear in AI-generated answers. When a hospital CIO asks ChatGPT "which revenue cycle management vendors have the best outcomes for academic medical centers" or a Chief Pharmacy Officer asks Perplexity "which specialty pharmacy management platforms support 340B compliance for community health centers," the AI answers determine which vendors make the initial consideration set before any vendor is contacted. For life sciences companies, the same dynamic applies: when a Vice President of Commercial Operations asks ChatGPT "which patient support program vendors specialize in rare disease therapy adherence" or a medtech CMO asks Perplexity "which regulatory affairs consultants have the most experience with FDA 510k submissions for Class II diagnostic devices," those AI answers determine which firms get onto the RFP shortlist. Healthcare and life sciences companies not appearing in those answers are being excluded from evaluations before they have any opportunity to present clinical or commercial evidence.
TPG's AXO Diagnostic scores your healthcare brand's current visibility across ChatGPT, Perplexity, Gemini, and Claude for the specific buyer queries that matter most to your pipeline, identifies the content and technical architecture gaps, and delivers a prioritized 90-day AEO roadmap. All AEO content produced for healthcare clients is run through regulatory review to ensure FDA compliance for any promoted products and HIPAA compliance for any content touching provider or patient information.
Measuring Revenue Marketing ROI in Healthcare
How to connect marketing activity to contracts signed, not MQL counts, so the CFO sees marketing as a growth investment with provable return.
How do healthcare companies prove marketing's contribution to revenue across 24-month evaluation cycles and multi-stakeholder accounts?
Healthcare companies prove marketing's contribution to revenue by building attribution systems that handle the three specific complexities of healthcare B2B sales: 24-month attribution windows that span multiple fiscal years, multi-stakeholder influence at the same health system or IDN, and the distinction between marketing-influenced and marketing-sourced pipeline that healthcare CFOs rightly scrutinize. The 24-month attribution window means that a content download, webinar attendance, or trade show interaction in Q1 of one year may not contribute to a contract close until Q3 or Q4 of the following year. Most CRM and marketing automation systems expire attribution data in 90 to 180 days, making it appear that marketing contributed nothing to deals that took 18 months to close. This attribution gap causes healthcare marketing teams to be chronically underfunded because the CFO cannot see the contribution.
TPG builds revenue attribution systems for healthcare companies that hold influence data for 24 to 36 months, track engagement at the account level across all buying committee members, and connect marketing program activity to contract value at signing with enough fidelity for the CFO to use in budget allocation decisions. Healthcare clients who implement proper attribution typically redirect 25 to 35 percent of marketing budget from programs generating activity to programs actually influencing contracts.
Healthcare Companies That Turned Evidence Into Pipeline
"TPG helped us implement a structured lead management process that brought global consistency to our sales and marketing operations. Their expertise in aligning teams, optimizing campaigns, and improving visibility into revenue impact has been instrumental in transforming how we measure and scale marketing success."
Lawrence DiCapua, Leader, Revenue Marketing Center of Excellence, GE Healthcare
Read the full case study →"Building a world-class marketing operations function requires more than process changes — it demands the right strategy, structure, and expertise. TPG helped us create a scalable system that not only streamlined our operations but also accelerated execution and drove measurable business impact."
Kevin Young, VP Marketing, TraceLink
Read the full case study →"TPG didn't just help us migrate platforms — they helped us rethink how we approach marketing on a global scale. Their expertise ensured a seamless transition while giving us the structure and agility to better connect with customers across 24 markets."
Ed Stening, International Head of Digital, Zoetis
Read the full case study →"TPG helped us build a scalable marketing organization that optimized our growth trajectory while delivering significant cost savings, including $75K in website development efficiencies."
Marketing Leadership, Ethos Veterinary Health
Read the full case study →Revenue Marketing for Healthcare & Life Sciences: Common Questions
What is revenue marketing for healthcare and life sciences companies?
Revenue marketing for healthcare and life sciences is the discipline of connecting every marketing investment directly to measurable pipeline and closed contracts, within FDA, HIPAA, and clinical evidence constraints. Healthcare companies sell complex solutions through 18-to-24-month buying cycles involving committees of clinical, administrative, IT, legal, and procurement stakeholders, each with different evidence standards and decision authority.
TPG's RM6 framework operationalizes revenue marketing across six pillars calibrated to healthcare realities: clinical evidence requirements, 24-month buying cycles, IDN and health system purchasing committees, and regulatory constraints governing every marketing communication. Healthcare and life sciences clients implementing RM6 with TPG typically see 188 percent pipeline growth within 18 months.
How do healthcare companies do demand generation under FDA and HIPAA constraints?
Healthcare companies generate demand under FDA and HIPAA constraints by building marketing systems with compliance architecture designed from the start. HIPAA compliance requires consent management infrastructure, BAA coverage for all marketing technology vendors, PHI segregation, and audit trails. FDA compliance for pharmaceutical and medical device marketing requires pre-approved claim libraries and MLR review workflows built into campaign production.
TPG builds demand generation systems that include pre-approved content templates, automated review workflows, and claim libraries across SEC, FINRA, FDA, and HIPAA regulatory frameworks. These systems let marketing launch faster while giving legal and regulatory complete visibility and control.
How does ABM work for healthcare companies selling to hospitals, IDNs, or health systems?
ABM for healthcare companies selling to hospitals and IDNs requires mapping a buying committee of six or more stakeholders: the clinical lead, the CIO, the CFO, legal and compliance, the value analysis committee, and operations leadership. Each requires different content meeting their specific evidence standard. Most healthcare marketing programs reach one or two of these stakeholders. ABM reaches all of them simultaneously.
TPG has implemented ABM programs for 28+ healthcare and life sciences clients, built with HIPAA compliance architecture from the first program design. Our healthcare ABM programs average 40 to 60 percent higher conversion from target IDN and health system accounts compared to broad demand generation.
What MarTech platforms work for healthcare and are HIPAA compliant?
Healthcare MarTech platforms that sign Business Associate Agreements include Salesforce Health Cloud and Marketing Cloud, HubSpot (for covered entities), Marketo (Adobe), Oracle Eloqua, and Microsoft Azure-hosted Dynamics 365. Veeva CRM and Vault are standard in pharmaceutical and medical device commercial operations for FDA-compliant content management and HCP engagement tracking.
TPG is platform-agnostic and runs HIPAA-aware platform selection processes evaluating BAA coverage, PHI data handling, clinical system integration requirements, and regulatory content management needs before recommending any platform.
How do healthcare companies use AI in marketing without violating HIPAA?
Healthcare companies use AI in marketing safely by restricting AI model inputs to non-PHI data and ensuring AI systems touching potentially protected information operate under a BAA and within HIPAA Security Rule requirements. Safe applications include third-party intent data analysis, predictive lead scoring on CRM engagement data, content personalization using segment-level attributes, and marketing attribution modeling. Applications requiring careful review include systems that infer prescribing patterns or access clinical metrics that could constitute PHI.
TPG's R.A.I.N. framework includes data classification to ensure PHI segregation, BAA coverage for all AI components, and human-in-the-loop review for any AI-generated content subject to FDA promotional regulations.
What content marketing strategies work for healthcare and life sciences buyers?
Healthcare content that works is built around the evidence hierarchy each buyer uses to make decisions. Clinicians require peer-reviewed outcomes data, independent studies, and peer institution references. Hospital administrators require total cost of ownership analysis and comparable health system case studies. Health IT buyers require security certifications and integration documentation. Formulary committees require FDA-approved labeling and comparative effectiveness data. Pharmaceutical procurement requires pharmacoeconomic analysis and safety profiles meeting MLR approval standards.
TPG builds healthcare content strategies with regulatory review built into production workflows, reducing legal cycle times while ensuring compliance. Distribution increasingly requires AEO optimization because clinical and administrative buyers, as well as pharma and medtech commercial teams, now routinely use AI assistants to research vendors before engaging sales.
How do healthcare companies measure marketing ROI across 24-month sales cycles?
Healthcare companies measure marketing ROI by building attribution systems that hold influence data across 24-to-36-month buying cycles, track engagement at the account level across all buying committee members, and connect program activity to contract value at signing. Most CRM systems expire attribution data in 90 to 180 days, creating a gap that makes marketing appear to contribute nothing to deals that took 18 months to close and causing healthcare marketing teams to be chronically underfunded.
TPG builds revenue attribution systems for healthcare that hold influence data for the full length of healthcare buying cycles and connect to contract value at close. Healthcare clients who implement proper attribution typically redirect 25 to 35 percent of budget from activity-generating programs to contract-influencing programs.
What is AXO and why do healthcare companies need it?
AXO stands for AI Experience Optimization, and it is TPG's methodology for ensuring healthcare and life sciences brands appear prominently when AI systems like ChatGPT, Perplexity, Gemini, and Claude answer questions from clinical and administrative buyers researching vendors. Healthcare buyers now routinely start vendor research by asking AI assistants for recommendations before visiting any vendor website. If your company is not appearing in those AI-generated answers, you are being excluded from the initial consideration set before you can present any clinical or commercial evidence.
TPG's AXO Diagnostic scores your healthcare brand's visibility across four major AI platforms, identifies content and technical gaps, and delivers a 90-day AEO roadmap. All AEO content for healthcare clients is produced under regulatory review for FDA and HIPAA compliance.
Clinical Outcomes Are Evidence-Based. Your Marketing Should Be Too.
TPG has built revenue marketing systems for 28+ healthcare and life sciences companies that satisfy FDA guidelines, pass HIPAA review, meet the evidence standards of clinical buyers, and deliver measurable results. GE Healthcare: $2B in opportunities influenced, $600M closed won. TraceLink: $20M in new revenue generated. Zoetis: $200M+ annual pipeline impact across 24 markets. 19 years of practice. One guarantee: results or you don't pay.
Satisfaction guaranteed: redo or no charge.